非瓣膜性持续心房颤动患者抗血栓治疗临床调查

对我院从1997年1月至2002年12月住院的535例非瓣膜性持续心房颤动(简称房颤)患者病历资料进行逐项调查,分析房颤病因、抗血栓治疗及并发血栓栓塞性疾病情况。结果:病因以高血压最常见(38.5%),其次为冠心病(34.6%)。使用华法令52例(9.7%),维持INR在2.0~3.0范围,无1例出现血栓栓塞性疾病及严重出血。使用阿斯匹林331例(61.9%),用量为平均75mg/d出现血栓栓塞性疾病76例(占23%)。未使用任何抗血栓治疗者152例(28.4%),出现血栓栓塞性疾病36例(23.7%)。结论:华法令能明显减少房颤相关血栓栓塞性疾病的发生,小剂量阿斯匹林则无此作用。

Clinical Investigation of Anti-thrombo Therapy on Patients With Nonvalvular Persistent Atrial Fibrillation

Five hundred and thirty-five cases with nonvalvular persistent atrial fibrillation from January 1997 to December 2002 in our hospital were retrospectively analyzed on the cause of atrial fibrillation, effect of anti-thrombo therapy and occurrence of thrombo-embolism.Results:52 cases(9.7%) were treated with warfarin and maintained the international rate(INR) at 2.0~3.0 and nobody showed the symptom of thrombo-embolism and serious bleeding. While in 331 cases (61.9%) treated with aspirin (avreaging 75 mg/d) and 152 cases(28.4%) without use anti-thrombo therapy,thrombo-embolism was found in 76(23%) and 36(23.7%) patients respectively. Conclusion: Warfarin can significantly reduce the incidence of atrial fibrillation affiliated thrombo -embolism , while aspirin(75mg/d) can not prevent the occurrence of atrial fibrillation affiliated thrombo-embolism.